Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
Sue Bacon, VTE specialist – Quality Improvement at North Bristol NHS Trust, reposted from Firstkind Ltd on LinkedIn:
”It’s so important to ask this question – hospital acquired DVT and PE is not uncommon, and sometimes linked to lack of an assessment of your individual risk, but also, sadly, because patients do not understand enough and refuse the medication/devices.
Please, please ask.”
Firstkind Ltd shared on LinkedIn:
”Did you know?
More people die each year in the UK from hospital-acquired venous thromboembolism (VTE) than from breast cancer, AIDS, and traffic accidents combined.
VTE is a leading cause of preventable death in hospitals — yet it’s often overlooked.
The good news? Most cases are entirely preventable with timely risk assessments and appropriate treatment.
Innovative technologies like the geko device, which stimulates blood flow in the lower leg, are helping reduce VTE risk when traditional methods aren’t suitable.
If you or a loved one is admitted to hospital, don’t be afraid to ask: ‘Have I been assessed for blood clots?”
Stay updated with Hemostasis Today.
-
Jun 9, 2026, 17:55Can We Prevent Postpartum Blood Clots without Putting Most Women on Heparin? – RPTH Journal
-
Jun 9, 2026, 17:54Lucky Oseghale Oloboh: Health Is Power, Health Is Personal, and Health Is Our First Responsibility in Life’s Journey on Mother Earth
-
Jun 9, 2026, 17:53Ajay Samkaria: How ABO Subgroups Directly Impact Transfusion Safety
-
Jun 9, 2026, 17:51Alejandro González Veliz: Most Reported Aspirin Allergies Are Not True Hypersensitivity
-
Jun 9, 2026, 17:50Mary Cushman: It’s Time to Apply to Be on an ISTH SSC
-
Jun 9, 2026, 15:56Wolfgang Miesbach: A New Genetic Perspective on the Worldwide Burden of von Willebrand Disease
-
Jun 9, 2026, 15:34Shanon Marie Corsino: Nationwide Insights into Cancer-Associated Thrombosis in Filipino Patients
-
Jun 9, 2026, 15:20Murtuza Ali: Types of Blood Transfusions – A Quick Clinical Guide
-
Jun 9, 2026, 15:18Mital Jhaveri: TRACK Trial Findings Highlight the Unique Challenges of Advanced CKD